Measles Symptoms, Management, and Prevention

Clinical Presentation

The Centers for Disease Control and Prevention (CDC) reports that measles is characterized by a prodrome of fever, cough, coryza (runny nose), and conjunctivitis followed by a maculopapular rash that begins on the face and spreads downward to the trunk and extremities, with potential for severe complications including pneumonia and encephalitis 1, 2
The incubation period averages 10-12 days from exposure to prodrome and 14 days from exposure to rash (range: 7-18 days) 3, 4
Prodromal symptoms include fever, cough, coryza (runny nose), and conjunctivitis ("pink eye") 1, 2
Koplik spots (small white spots on a red background inside the mouth) appear during the prodrome and are considered pathognomonic for measles 1, 2
Diarrhea is the most common complication, followed by middle ear infection (otitis media), bronchopneumonia, and encephalitis (occurs in approximately 1 per 1,000 cases) 3, 4
Death occurs in 1-2 per 1,000 reported cases in the United States 3, 4

High-Risk Populations

Infants and young children face higher mortality risk than older children 3, 4
Adults experience higher complication rates 3, 4
Pregnant women may experience increased rates of premature labor, spontaneous abortion, and low birth weight infants 3, 4
Immunocompromised individuals may develop severe, prolonged infection, sometimes without the typical rash 3, 4

Management

The American Academy of Pediatrics recommends vitamin A supplementation for all children with clinical measles 5
Children under 12 months should receive 100,000 IU orally, while children over 12 months should receive 200,000 IU orally 5
Repeat dose for children with complicated measles on day 2 5
Additional dose 1-4 weeks later for those with vitamin A deficiency eye symptoms 5
Antibiotics should be used for secondary bacterial infections, particularly pneumonia 5
Oral rehydration therapy should be used for diarrhea 5

Prevention

The Centers for Disease Control and Prevention (CDC) recommends vaccination as the cornerstone of measles prevention 1
The first dose of MMR (measles-mumps-rubella) vaccine should be given at 12-15 months of age, and the second dose at 4-6 years of age 1
Post-exposure prophylaxis with MMR vaccine may provide protection if given within 72 hours of exposure 5
Undernutrition is not a contraindication for measles vaccination; it should be considered a strong indication for vaccination 5
Unimmunized persons infected with HIV should receive the vaccine unless severely immunosuppressed 1, 5

Prognosis

The case fatality rate in the United States is 1-2 per 1,000 reported cases 3, 4
The case fatality rate in developing countries can be as high as 25% 3, 4
Long-term sequelae may include permanent brain damage from encephalitis 3, 4
Subacute sclerosing panencephalitis (SSPE) is a rare but fatal late complication that appears years after infection 3, 4, 6

Introduction to SSPE

Measles can cause subacute sclerosing panencephalitis (SSPE) in adults, though it occurs less frequently than in children who contracted measles at younger ages 7
SSPE is a rare but fatal late complication of measles infection that can appear years after the initial infection in immunologically normal individuals 7

Clinical Distinctions and Prevention

The Centers for Disease Control and Prevention and the Advisory Committee on Immunization Practices definitively state that MMR vaccine does not increase SSPE risk, and when rare cases occur in vaccinated individuals, evidence indicates they had unrecognized measles infection before vaccination 7
Measles vaccination remains the only effective prevention strategy for SSPE, and widespread vaccination has essentially eliminated SSPE from countries with high vaccination coverage, as noted by the World Health Organization 7

Measles Complications in High-Risk Populations

High-Risk Populations

Patients on high-dose corticosteroids (≥20 mg/day prednisone for >2 weeks) are considered immunosuppressed and at higher risk, according to the Autoimmunity Reviews guideline 8, 9

Measles-Associated Pharyngitis

Clinical Characteristics

The presence of conjunctivitis, cough, hoarseness, coryza, and Koplik spots suggests measles rather than streptococcal infection, as these features are characteristic of a systemic viral illness affecting multiple organ systems 10
Measles is a systemic infection affecting multiple organ systems, not isolated to the pharynx, and the pharyngitis in measles is self-limited and does not benefit from antimicrobial therapy unless secondary bacterial superinfection develops 10

Treatment and Management

The American Academy of Pediatrics and Infectious Diseases Society of America recommend against prescribing antibiotics for measles-associated pharyngitis unless there is documented secondary bacterial infection, as antimicrobial therapy is of no proven benefit for viral pharyngitis and unnecessarily exposes patients to expense, adverse effects, and contributes to antimicrobial resistance 10

Measles Management and Prevention

Diagnostic Confirmation and Isolation

The American Academy of Pediatrics recommends that all suspected measles cases must be reported immediately and laboratory confirmed, with measles-specific IgM antibody testing and RT-PCR for measles virus RNA detection considered for diagnosis 11, 12
Patients with measles are contagious from 4 days before rash onset to 4 days after rash appears, and immediate airborne precautions should be implemented 11, 12
The Centers for Disease Control and Prevention suggests identifying and notifying all contacts for post-exposure prophylaxis consideration, with MMR vaccine within 72 hours of exposure potentially providing protection for susceptible contacts 11, 12

Infection Control and Treatment

The American Academy of Pediatrics advises implementing immediate isolation measures, including airborne precautions, when Koplik spots are identified, to prevent further transmission 12
The World Health Organization recommends supportive care, including oral rehydration therapy and monitoring for severe complications, for patients with measles 11, 12

Measles Complications in High-Risk Populations

Vaccination and Management Guidelines

The Centers for Disease Control and Prevention recommends that HIV-infected children without severe immunosuppression should receive MMR vaccine at 12 months of age, with consideration for a second dose as early as 28 days after the first dose, to reduce the risk of severe complications from measles 13, 14
Children with severe immunosuppression should NOT receive measles vaccination due to risk of vaccine-associated disease, as stated by the Centers for Disease Control and Prevention 13
The American Academy of Pediatrics and the Centers for Disease Control and Prevention suggest that HIV-infected children are at increased risk for severe complications if infected with measles, including progressive measles pneumonitis and prolonged infection that may occur without the typical rash 13, 14

Measles: Evidence‑Based Clinical and Public‑Health Guidelines

Epidemiology

The incubation period averages 10–12 days from exposure to the prodromal phase and about 14 days to rash onset (range 7–18 days). 15
Individuals are contagious from 4 days before rash appearance through 4 days after rash onset. 16
Immunocompromised persons may continue shedding measles virus for several weeks after acute illness and can present without the typical rash. 15

Clinical Presentation

Measles classically begins with a prodrome of fever ≥ 38.3 °C, cough, coryza, and conjunctivitis, followed by a maculopapular rash lasting ≥ 3 days. 17

Laboratory Diagnosis

Measles‑specific IgM testing should be obtained at the first clinical encounter, even before results are available, to avoid delays in public‑health actions. 17
If the initial IgM test is negative within the first 72 hours of rash onset, a repeat specimen should be collected ≥ 72 hours after rash onset because early IgM may be undetectable with some assays. 18
Measles IgM levels typically peak ≈ 10 days after rash onset and remain detectable for at least one month. 17
Urine or nasopharyngeal specimens for viral isolation and genetic characterization should be collected as close to rash onset as possible. 18
False‑positive IgM results can occur (e.g., with parvovirus infection); confirmatory testing with a direct‑capture IgM EIA is advised when no epidemiologic link is identified. 17

Immediate Management

Patients should be placed under airborne isolation (negative‑pressure room, N95 respirators for all staff) for at least 4 days after rash onset, regardless of staff immunity status. 16
Health authorities (local or state) must be notified immediately after confirming a measles case, as a single case constitutes an urgent public‑health event. 17

Complications

The most common complications are diarrhea, otitis media, and bronchopneumonia. 15
Encephalitis occurs in roughly 1 per 1,000 measles cases and often leaves permanent neurologic sequelae. 15
Mortality in the United States is 1–2 per 1,000 reported cases; case‑fatality rates can reach 25 % in developing nations. 15
Pneumonia and acute encephalitis are the leading causes of measles‑related death. 15
Infants, young children, and adults have higher risks of death and severe complications compared with older children and adolescents. 15
Pregnant women experience increased rates of premature labor, spontaneous abortion, and low birth‑weight infants. 15
Severely immunocompromised individuals may develop prolonged, severe infection, sometimes without the classic rash. 15
Subacute sclerosing panencephalitis (SSPE) is a rare, fatal, progressive CNS disease that can appear years after infection; widespread vaccination has essentially eliminated SSPE in the United States. 15

Post‑Exposure Prophylaxis (PEP)

Healthcare workers lacking documented immunity must be excluded from work for days 5–21 after exposure, even if they receive immune‑globulin (IG) prophylaxis. 16
Standard IG dose for measles PEP: 0.25 mL/kg intramuscularly (maximum 15 mL) administered within 6 days of exposure. 19
For immunocompromised contacts, the IG dose is increased to 0.5 mL/kg IM (maximum 15 mL) within 6 days of exposure. 16
Live measles vaccine should be deferred for at least 3 months after IG administration because passive antibodies can neutralize the vaccine. 19

Vaccination Recommendations

Two doses of measles‑containing vaccine (MMR) should be administered at least 28 days apart. 16
High‑risk groups—college students and healthcare workers—must have documentation of two vaccine doses. 16
International travelers should receive two documented doses before departure. 19
During outbreaks, infants aged 6–11 months may receive an early measles vaccine dose; they must be revaccinated at 12–15 months and again before school entry. 18
Individuals without acceptable evidence of immunity should be vaccinated or excluded from outbreak settings until 21 days after the rash onset of the last case. 18

Contraindications & Timing

Pregnancy is an absolute contraindication to measles vaccination. 19
Severe immunocompromise (e.g., primary immune deficiency, leukemia, lymphoma, generalized malignancy, or immunosuppressive therapy) is an absolute contraindication. 19
Measles vaccine should be given at least 14 days before, or deferred for ≥ 6 weeks (preferably ≥ 3 months) after, receipt of IG, whole blood, or other antibody‑containing blood products. 19

Management of Post‑Measles Oral Candidiasis

Epidemiology & Pathophysiology

Oral candidiasis (pseudomembranous form) is the most common oral fungal infection and typically presents as whitish plaques that appear after measles‑induced immunosuppression. 20, 21
The pseudomembranous lesions appear as creamy‑white, plaque‑like patches on the buccal mucosa, oropharynx, or tongue and can be readily scraped off. 20, 21

Diagnostic Approach

Clinical diagnosis is usually sufficient when characteristic white plaques that can be scraped off are observed. 20, 21
For microbiological confirmation (e.g., after treatment failure or recurrent disease), obtain a sample by scraping the lesion with a tongue depressor and culture on fungal‑selective media. 20

Treatment Recommendations

First‑Line Topical Therapy

Topical agents (e.g., nystatin suspension or clotrimazole troches) are appropriate for mild to moderate disease; systemic therapy is reserved for severe cases or treatment failure. (guideline recommendation inferred from cited evidence) 20, 21

Systemic Therapy

Fluconazole is the preferred oral systemic antifungal for moderate to severe oral candidiasis or when topical therapy fails. 20, 21
Systemic antifungal therapy is especially important in the post‑measles setting because of the degree of immunosuppression. 20

Duration & Monitoring

Treatment should be continued for at least 7–14 days; clinicians should assess response within 3–5 days. Lack of improvement suggests resistant organisms or an incorrect diagnosis. 20, 21
If the patient does not improve within 5–7 days, obtain cultures with species identification and susceptibility testing, and consider alternative diagnoses. 20, 21

Risk Factors for Treatment Failure

Prior exposure to fluconazole increases the risk of azole‑resistant Candida species. 20, 21
Infections caused by non‑albicans species (e.g., C. krusei, C. glabrata) have intrinsically reduced susceptibility to azoles. 20, 21
Severe immunosuppression following measles raises the likelihood of refractory candidiasis. 20, 21

Prevention & Prophylaxis

Avoid unnecessary antibiotic use, which can predispose to candidal overgrowth. 22
Primary antifungal prophylaxis is not recommended for immunocompetent patients recovering from measles. 20, 23

Escalation of Care

Development of dysphagia or odynophagia may indicate esophageal extension and warrants endoscopic evaluation. 20, 23, 22
Recurrent oral candidiasis episodes should prompt investigation for underlying immunodeficiency beyond the transient measles‑related immunosuppression. 20, 21